Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit

Srdan Verstovsek, Cem Akin, Taghi Manshouri, Alfonso Quintás-Cardama, Ly Huynh, Paul Manley, Ayalew Tefferi, Jorge Cortes, Francis J. Giles, Hagop Kantarjian

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)1365-1370
Number of pages6
JournalLeukemia Research
Volume30
Issue number11
DOIs
StatePublished - Nov 1 2006
Externally publishedYes

Fingerprint

Systemic Mastocytosis
Mast Cells
Codon
Protein-Tyrosine Kinases
Mutation
Bone Marrow Cells
Bone Marrow
Phosphorylation
Cell Proliferation
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
2-aminopyrimidine
Apoptosis
Cell Line
Imatinib Mesylate
Pharmaceutical Preparations

Keywords

  • AMN107
  • c-Kit kinase inhibitor
  • Imatinib
  • Mastocytosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Verstovsek, S., Akin, C., Manshouri, T., Quintás-Cardama, A., Huynh, L., Manley, P., ... Kantarjian, H. (2006). Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leukemia Research, 30(11), 1365-1370. https://doi.org/10.1016/j.leukres.2006.04.005

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. / Verstovsek, Srdan; Akin, Cem; Manshouri, Taghi; Quintás-Cardama, Alfonso; Huynh, Ly; Manley, Paul; Tefferi, Ayalew; Cortes, Jorge; Giles, Francis J.; Kantarjian, Hagop.

In: Leukemia Research, Vol. 30, No. 11, 01.11.2006, p. 1365-1370.

Research output: Contribution to journalArticle

Verstovsek, S, Akin, C, Manshouri, T, Quintás-Cardama, A, Huynh, L, Manley, P, Tefferi, A, Cortes, J, Giles, FJ & Kantarjian, H 2006, 'Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit', Leukemia Research, vol. 30, no. 11, pp. 1365-1370. https://doi.org/10.1016/j.leukres.2006.04.005
Verstovsek, Srdan ; Akin, Cem ; Manshouri, Taghi ; Quintás-Cardama, Alfonso ; Huynh, Ly ; Manley, Paul ; Tefferi, Ayalew ; Cortes, Jorge ; Giles, Francis J. ; Kantarjian, Hagop. / Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. In: Leukemia Research. 2006 ; Vol. 30, No. 11. pp. 1365-1370.
@article{bad9bd9456b54108bddf40cb859e3d8e,
title = "Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit",
abstract = "Most adults with systemic mastocytosis (SM) carry an activating mutation in the codon 816 of c-kit. We investigated the activity of the new tyrosine kinase inhibitor AMN107 on c-kit mutated mast cell lines and bone marrow samples from patients with SM and compared it to that of imatinib mesylate, a tyrosine kinase inhibitor effective in some patients with SM. In HMC-1560 mast cells carrying wild-type codon 816 c-kit, AMN107 was very effective and as potent as imatinib in inhibiting cellular proliferation and inducing apoptosis (P < 0.0823). By contrast, in HMC-1560,816 cells bearing a c-kit mutation in codon 816, neither drug exerted a significant effect (P < 0.0015). AMN107 was also as effective as imatinib in inhibiting phosphorylation of c-kit in HMC-1560 cells. However, AMN107 had little effect on ex vivo survival of bone marrow mast cells with 816 c-kit mutation obtained from patients with SM. Based upon our results, AMN107 and imatinib are equipotent against mast cells with wild-type c-kit and those harboring the juxtamembrane D560G c-kit mutant but have no significant activity over the dose range tested against cells expressing the c-kit D816V mutant tyrosine kinase.",
keywords = "AMN107, c-Kit kinase inhibitor, Imatinib, Mastocytosis",
author = "Srdan Verstovsek and Cem Akin and Taghi Manshouri and Alfonso Quint{\'a}s-Cardama and Ly Huynh and Paul Manley and Ayalew Tefferi and Jorge Cortes and Giles, {Francis J.} and Hagop Kantarjian",
year = "2006",
month = "11",
day = "1",
doi = "10.1016/j.leukres.2006.04.005",
language = "English (US)",
volume = "30",
pages = "1365--1370",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit

AU - Verstovsek, Srdan

AU - Akin, Cem

AU - Manshouri, Taghi

AU - Quintás-Cardama, Alfonso

AU - Huynh, Ly

AU - Manley, Paul

AU - Tefferi, Ayalew

AU - Cortes, Jorge

AU - Giles, Francis J.

AU - Kantarjian, Hagop

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Most adults with systemic mastocytosis (SM) carry an activating mutation in the codon 816 of c-kit. We investigated the activity of the new tyrosine kinase inhibitor AMN107 on c-kit mutated mast cell lines and bone marrow samples from patients with SM and compared it to that of imatinib mesylate, a tyrosine kinase inhibitor effective in some patients with SM. In HMC-1560 mast cells carrying wild-type codon 816 c-kit, AMN107 was very effective and as potent as imatinib in inhibiting cellular proliferation and inducing apoptosis (P < 0.0823). By contrast, in HMC-1560,816 cells bearing a c-kit mutation in codon 816, neither drug exerted a significant effect (P < 0.0015). AMN107 was also as effective as imatinib in inhibiting phosphorylation of c-kit in HMC-1560 cells. However, AMN107 had little effect on ex vivo survival of bone marrow mast cells with 816 c-kit mutation obtained from patients with SM. Based upon our results, AMN107 and imatinib are equipotent against mast cells with wild-type c-kit and those harboring the juxtamembrane D560G c-kit mutant but have no significant activity over the dose range tested against cells expressing the c-kit D816V mutant tyrosine kinase.

AB - Most adults with systemic mastocytosis (SM) carry an activating mutation in the codon 816 of c-kit. We investigated the activity of the new tyrosine kinase inhibitor AMN107 on c-kit mutated mast cell lines and bone marrow samples from patients with SM and compared it to that of imatinib mesylate, a tyrosine kinase inhibitor effective in some patients with SM. In HMC-1560 mast cells carrying wild-type codon 816 c-kit, AMN107 was very effective and as potent as imatinib in inhibiting cellular proliferation and inducing apoptosis (P < 0.0823). By contrast, in HMC-1560,816 cells bearing a c-kit mutation in codon 816, neither drug exerted a significant effect (P < 0.0015). AMN107 was also as effective as imatinib in inhibiting phosphorylation of c-kit in HMC-1560 cells. However, AMN107 had little effect on ex vivo survival of bone marrow mast cells with 816 c-kit mutation obtained from patients with SM. Based upon our results, AMN107 and imatinib are equipotent against mast cells with wild-type c-kit and those harboring the juxtamembrane D560G c-kit mutant but have no significant activity over the dose range tested against cells expressing the c-kit D816V mutant tyrosine kinase.

KW - AMN107

KW - c-Kit kinase inhibitor

KW - Imatinib

KW - Mastocytosis

UR - http://www.scopus.com/inward/record.url?scp=33748114504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748114504&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2006.04.005

DO - 10.1016/j.leukres.2006.04.005

M3 - Article

C2 - 16797704

AN - SCOPUS:33748114504

VL - 30

SP - 1365

EP - 1370

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 11

ER -